secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001213900-25-020064
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio files investor presentation on INKmune phase I/II in prostate cancer - no specific data disclosed
--------------------------------------------------------------------------------

- Preliminary phase I/II results for INKmune in metastatic castration-resistant prostate cancer highlighted in new investor deck.
- No specific efficacy or safety data provided in the 8-K excerpt; full slide content not available.
- Presentation focuses on in vivo activation of memory-like NK cells (mlNK) using INKmune.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/0001213900-25-020064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/ea0233142-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-020064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer